Assuntos
Anormalidades Múltiplas/diagnóstico , Adolescente , Índice de Apgar , Córnea/anormalidades , Anormalidades Craniofaciais/diagnóstico , Orelha/anormalidades , Evolução Fatal , Feminino , Idade Gestacional , Deformidades da Mão/diagnóstico , Hérnia Diafragmática/diagnóstico , Humanos , Recém-Nascido , Masculino , Pescoço/anormalidades , Nariz/anormalidades , Gravidez , Resultado da Gravidez , Síndrome , Ultrassonografia Pré-Natal/métodosAssuntos
Benzotiadiazinas , Broncodilatadores/efeitos adversos , Doenças em Gêmeos , Diuréticos , Humanos , Hiponatremia/induzido quimicamente , Síndrome de Secreção Inadequada de HAD/induzido quimicamente , Recém-Nascido , Respiração Artificial , Síndrome do Desconforto Respiratório do Recém-Nascido/tratamento farmacológico , Inibidores de Simportadores de Cloreto de Sódio/efeitos adversos , Teofilina/efeitos adversosRESUMO
OBJECTIVE: To evaluate safety and efficacy of recombinant human erythropoietin (r-HuEPO)in reducing the need for red cell transfusions in anemia of prematurity. METHODS: forty -two preterm infants (gestational age <32 weeks) were randomly assigned to a "treatment" group (r-HuEPO 400 units/kg every alternate day * 10 doses) or "no treatment" (control) group. All infants on enteral feeds received oral iron 3 mg/kg/day, graded up to 6 mg/kg/day. RESULTS: Higher reticulocyte counts in week 2 and 3 and higher hemoglobin levels in week 4 were noted after treatment with r-HuEPO. Despite stumulated erythropoiesis, the frequency of transfusions could not be reduced with r-HuEPO therapy.Overall, Phlebotomy losses, frequency and volume of redcell transfusions were significantly more in neonates with birthweight <1000 grams compared with those with birthweight >1000 grams (p<0.05). Associated side effects of r-HuEPO such as neutropenia,sepsis, hypertension or increased risk of late death did not occur. CONCLUSION:r-HuEPO therapy was safe without any side effects.Inability of r-HuEPO therapy to minimize red cell transfusions for anemia of prematurity may be explained by a relatively strict red-cell transfusion policy and the desired degree of treatment effect.